Physician profile
Carson Bee
NPI 1790120202
$1,728.40
in general payments reported to CMS, 2019-2025
11 companies · $13.66 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $66.73 · 2021: $404 · 2022: $119 · 2023: $593 · 2024: $429 · 2025: $13.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $868.47 | 2020-2024 | Clareon, Acrysof Iq Panoptix Uv Iol, Argos |
| Johnson & Johnson Surgical Vision, INC. | $247.87 | 2019-2023 | Tecnis Simplicity |
| Abbvie INC. | $195.20 | 2023-2025 | Durysta, Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $184.93 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.88 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $54.45 | 2022-2024 | Vyzulta, Miebo, Lotemax Sm |
| Thea Pharma INC. | $40.30 | 2024 | Iyuzeh |
| Allergan, INC. | $35.24 | 2019-2021 | |
| Oyster Point Pharma, INC. | $18.82 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $16.61 | 2019 | |
| Ivantis, INC | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Bee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.